Apellis Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Apellis Pharmaceuticals generated cash of -$594,735,000, which is less than the previous year. Cash used in financing activities reached the amount of $394,499,000 last year. Net change in cash is therefore -$200,775,000.
Cash Flow
| 2014 | -9.94M | -19.94K | 18.83M |
|---|---|---|---|
| 2015 | -18.85M | 0 | 41.23M |
| 2016 | -26.00M | 0 | 14.86M |
| 2017 | -46.59M | 0 | 197.37M |
| 2018 | -131.24M | 0 | 131.90M |
| 2019 | -211.13M | -1.69M | 388.54M |
| 2020 | -160.48M | -316.98M | 692.17M |
| 2021 | -563.12M | 247.61M | 392.23M |
| 2022 | -513.74M | 59.89M | 365.65M |
| 2023 | -594.73M | -674K | 394.49M |
APLS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 553.07M | 641.75M | 567.04M | 351.98M | 176.26M | 175.64M | 24.86M | 36.00M | 13.62M | 4.75M |
Operating activities | ||||||||||
Net income | -528.62M | -652.17M | -746.35M | -344.87M | -304.70M | -127.50M | -51.00M | -27.12M | -46.51M | -10.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.70M | 1.48M | 1.49M | 637K | 239.68K | 0 | 11.93K | 0 | 0 | 6.59K |
Stock-based compensation expense | 105.94M | 91.08M | 70.66M | 45.37M | 21.14M | 0 | 5.41M | 1.07M | 545.70K | 659.15K |
| Deferred income tax benefit | 105.94M | 91.08M | 70.66M | 45.37M | 21.14M | 0 | 5.41M | 1.07M | 545.70K | 659.15K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 2.37M | -10.10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | -69.39M | -16.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 170K | 18.68M | 10.48M | -54K | -1.64M | 6.58M | 932.29K | 69.77K | 1.72M | 397.66K |
Cash generated by operating activities | -594.73M | -513.74M | -563.12M | -160.48M | -211.13M | -131.24M | -46.59M | -26.00M | -18.85M | -9.94M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -331.86M | -171.28M | -879.06M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -773K | -1.52M | -1.10M | -5.42M | -1.69M | 0 | 0 | 0 | 0 | -19.94K |
Acquisitions Net | 0 | -61.41M | -248.71M | 311.56M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -674K | 59.89M | 247.61M | -316.98M | -1.69M | 0 | 0 | 0 | 0 | -19.94K |
Financing activities | ||||||||||
Common Stock Issued | 384.38M | 380.12M | 398.02M | 381.42M | 109.58M | 131.19M | 150.06M | 0 | 1.71K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.78M | 1.57M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -322.87M | 184.21M | 0 | 26.36M | 0 | 0 | 0 |
Cash used in financing activities | 394.49M | 365.65M | 392.23M | 692.17M | 388.54M | 131.90M | 197.37M | 14.86M | 41.23M | 18.83M |
Net Change In Cash | -200.77M | -88.68M | 74.71M | 215.06M | 175.71M | 624.13K | 150.78M | -11.14M | 22.38M | 8.86M |
Cash at end of period | 352.29M | 553.07M | 641.75M | 567.04M | 351.98M | 176.26M | 175.64M | 24.86M | 36.00M | 13.62M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |